Showing results (2841-2850 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|January 1, 1989
In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibodyJ J Starling, R S Maciak, N A Hinson, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Human monocytes selectively bind to cells expressing the tumorigenic phenotypeH Shimizu, D Wyatt, R D Knowles, et al.
Cancer Immunology, Immunotherapy : CII|December 18, 2016
Bio-HMGB1 from breast cancer contributes to M-MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC-like cellsZhaoliang Su, Ping Ni, Peng She, et al.
Cancer Immunology, Immunotherapy : CII|December 23, 2016
Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancerRenate Pichler, Georg Gruenbacher, Zoran Culig, et al.
Cancer Immunology, Immunotherapy : CII|November 6, 2016
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpointsMaria Winqvist, Fariba Mozaffari, Marzia Palma, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patientsK Shiiba, R Suzuki, K Kawakami, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivativesS Sone, G Lopez-Berestein, I J Fidler
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Activation of antitumor properties in alveolar macrophages from protein-calorie malnourished ratsS Mutsuura, S Sone, E Tsubura, et al.
Cancer Immunology, Immunotherapy : CII|November 23, 2018
An alphavirus-based therapeutic cancer vaccine: from design to clinical trialAmrita Singh, Georgia Koutsoumpli, Stephanie van de Wall, et al.
Cancer Immunology, Immunotherapy : CII|February 17, 2019
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancerMartin Sebastian, Andreas Schröder, Birgit Scheel, et al.
Pageof 652